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Abstract
Aim: To investigate global patterns of cardiovascular risk factor control in patients
with type 2 diabetes mellitus (T2D).
Methods: DISCOVER is an international, observational cohort study of patients with
T2D beginning second-line glucose-lowering therapy. Risk factor management was
examined among eligible patients (ie, those with the risk factor) at study baseline.
Inter-country variability was estimated using median odds ratios (MORs).
Results: Among 14 343 patients with T2D from 34 countries, the mean age was 57.4
± 12.0 years and the median (interquartile range) duration of T2D was 4.2 (2.0–8.0)
years; 11.8% had documented atherosclerotic cardiovascular disease (ASCVD). Among
eligible patients, blood pressure was controlled in 67.5% (9284/13756), statins were
prescribed in 43.7% (5775/13208), angiotensin-converting enzyme inhibitors/angio-
tensin II receptor blockers were prescribed in 55.6% (5292/9512), aspirin was pre-
scribed in 53.3% of those with established ASCVD (876/1645), and 84.4%
(12 102/14343) were non-smoking. Only 21.5% of patients (3088/14343) had optimal
risk factor management (defined as control of all eligible measures), with wide inter-
country variability (10%–44%), even after adjusting for patient and site differences
(MOR 1.47, 95% confidence interval 1.24–1.66).
Conclusion: Globally, comprehensive control of ASCVD risk factors is not being
achieved in most patients, with wide variability among countries unaccounted for by
patient and site differences. Better country-specific strategies are needed to imple-
ment comprehensive cardiovascular risk factor control consistently in patients with
T2D to improve long-term outcomes.
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1 | INTRODUCTION
Cardiovascular disease remains the leading cause of morbidity and
mortality in patients with type 2 diabetes mellitus (T2D).1 Control of
individual risk factors such as blood pressure (BP), cholesterol,
smoking, and glycaemic status has been shown to reduce the inci-
dence of microvascular complications, cardiovascular complications,
and mortality in multiple trials.2–6 Moreover, interventions that
address multiple cardiovascular risk factors in combination can poten-
tially reduce the risk of cardiovascular events and death further.7–9
Despite this potential benefit, many patients with T2D have sub-
optimal control of cardiovascular risk factors, which is at least partly
attributable to the complex nature of chronic disease manage-
ment.10,11 Alarmingly, after the steady decline in atherosclerotic car-
diovascular disease (ASCVD) events among patients with T2D in the
last 15 years, there has been a recent resurgence in these morbid
ischaemic complications, particularly among those diagnosed before
the age of 65 years.12 These disturbing statistics highlight the urgent
public health imperative to refocus on aggressive cardiovascular risk
reduction programmes in patients living with T2D.
There is little contemporary evidence for patterns of cardiovascu-
lar risk factor control in patients with T2D globally that could help
inform care of these patients. As such, we used data from the
DISCOVER study (ClinicalTrials.gov identifiers NCT02322762 and
NCT02226822), a large observational study of patients with T2D in
whom second-line therapy was initiated. We used data from patients
from 38 countries across six continents to assess (a) global patterns of
optimal comprehensive cardiovascular risk factor control, (b) variability
among countries in achieving optimal risk factor control, and (c) the
degree to which variability could be explained by differences in patient
or site-level factors. The description of these practice patterns could
inform strategies to achieve better comprehensive cardiovascular risk
factor management and, in turn, improve long-term outcomes.
2 | METHODS
2.1 | Study population and protocol
DISCOVER (NCT02322762, NCT02226822) is a 3-year, non-inter-
ventional, prospective study assessing treatment and clinical out-
comes in patients with T2D in 38 countries beginning a second-line
therapy from September 2014 to June 13, 2016. Consecutive adult
(≥18 years) patients with T2D were invited to participate at initiation
of a second-line glucose-lowering treatment (add-on or switching)
after first-line oral monotherapy, dual therapy, or triple therapy.
Patients were excluded if they had type 1 diabetes, end-stage renal
disease on dialysis or renal transplant, were pregnant, or had received
insulin or another injectable agent or herbal/natural supplement alone
as a first-line therapy. The 38 countries were grouped by six regions
according to the World Health Organization (WHO) classification:
(a) Africa: Algeria, South Africa; (b) Americas: Argentina, Brazil,
Canada, Colombia, Costa Rica, Mexico, Panama; (c) South-East Asia:
India, Indonesia; (d) Europe: Austria, Czech Republic, Denmark,
France, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden,
Turkey; (e) Eastern Mediterranean: Bahrain, Egypt, Jordan, Kuwait,
Lebanon, Oman, Saudi Arabia, Tunisia, United Arab Emirates; and (f)
Western Pacific: Australia, China, Japan, Malaysia, South Korea, Tai-
wan. Data from patients enrolled from Denmark, Norway and Sweden
were not included in the present analysis owing to high rates of
incomplete baseline data for the Scandinavian countries. Data from
China were not available at the time of publication for administrative
reasons. Detailed review of literature and data from the national coor-
dinating investigators from each country regarding national diabetes
management practices (including type of physicians, practice location
and type, and geographical distribution) informed the selection of sites
within each country such that enrolled patients would represent as
much as possible the care within that country. Study site characteris-
tics according to WHO regions are described in Supplementary
Table 1. The study protocol was approved by clinical research ethics
committees in each participating country and the relevant institutional
review boards at each site. The protocol complied with the Declara-
tion of Helsinki, the International Conference on Harmonisation of
Good Clinical Practice, and the local regulations for clinical research.
All study participants provided written informed consent.
Data on patient demographics, socio-economic factors, medical
history, comorbidities, laboratory and vital status measurements, micro-
and macrovascular complications, and medications were collected using
a standardized electronic case report form.13 Presence of cardiovascu-
lar risk factors,such as hypertension and hyperlipidaemia, were defined
as per local investigator and per care guidelines used in that country.
ASCVD was defined as presence of history of coronary artery disease,
cerebrovascular disease or peripheral vascular disease, also as reported
by local site investigators. Any microvascular complication was defined
as presence of either diabetic retinopathy, nephropathy or neuropathy.
As the study was observational in nature, all variables collected were
measured during routine clinical care, and no additional measurement
of laboratory or clinical variables was mandated.
2.2 | Definition of optimal cardiovascular risk
factor management
Based on international diabetes guidelines,14,15 optimal cardiovascular
risk factor management was defined as control of all of the following
risk factors among eligible patients: (a) systolic BP <140 mmHg
(all patients); (b) statin prescription (patients aged ≥40 years or
with ASCVD); (c) non-smoking status (all patients); (d) angiotensin-
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converting enzyme (ACE) inhibitor/angiotensin II receptor blocker
(ARB) prescription (patients with hypertension or albuminuria); and
(e) daily aspirin (patients with established ASCVD). As eligibility for the
DISCOVER study included initiation of second-line glucose-lowering
therapy, glycated haemoglobin (HbA1c) levels at presentation were
likely to be suboptimally controlled in the majority of patients; thus
glycaemic control was not included in the analysis of risk factor con-
trol. Optimal comprehensive cardiovascular risk factor control was
defined as control of all eligible risk factors. Given the increasing focus
of guidelines on statin treatment regardless of cholesterol level, LDL
cholesterol concentration was not used to define optimal lipid control.
Lifestyle counselling regarding physical activity and diet could not be
reliably assessed owing to high rates of missing data.
We also conducted a secondary analysis and reported rates of indi-
vidual risk factor control based on the following definitions: (a) systolic
BP < 140 mmHg only among patients with history of reported hyper-
tension; (b) LDL cholesterol <2.59 mmol/L among patients with a lipid
panel checked within a year of baseline; (c) aspirin use for primary pre-
vention (among patients aged 40 years or older at higher cardiovascular
risk (defined as co-existing comorbidities of hypertension, hyper-
lipidaemia, chronic kidney disease or heart failure).
2.3 | Statistical analysis
Only baseline assessment data were used for these analyses. Continu-
ous variables were described using mean and SD or median and inter-
quartile range; categorical variables were described as frequency.
Rates of control of each cardiovascular risk factor and the com-
posite of optimal cardiovascular risk factor control were calculated
globally and for each WHO region. Using hierarchical logistic regres-
sion models, these global and WHO region-specific rates were
adjusted for age, sex, history of ASCVD, and duration of T2D.
Intercountry variability in achieving optimal comprehensive car-
diovascular risk factor control was explored using median odds ratios
(MORs), which estimate the median value of the odds ratios obtained
from comparing the odds of achieving optimal comprehensive cardio-
vascular risk factor control between two patients with identical risk
factors from two randomly selected countries (ratio of the country
with the highest odds and the country with the lowest odds, there-
fore, the MOR is always greater than or equal to 1). An MOR of 1 indi-
cates no country-level variation in risk factor control, with higher
MORs representing increased variability in risk factor control due to
country, independent of patient- or site-level differences. The initial
model included patient factors only (age, sex, body mass index, educa-
tion, employment, ASCVD, duration of T2D, hypertension, hyper-
lipidaemia, smoking, heart failure, chronic kidney disease,
microvascular disease), with a second model also including site-level
characteristics (centre type [primary care, community, teaching centre,
diabetes centre] and location [urban vs. rural], provider type, patient
volume at enrolling centre, and availability of specialty care).
Patient sociodemographic and clinical characteristics were com-
pared between groups with suboptimal and optimal cardiovascular
risk factor control using the t-test or Wilcoxon's rank sum test for
continuous variables and the chi-squared or Fisher's exact test for cat-
egorical variables. A multivariable hierarchical logistic regression
model was built to identify patient and site factors associated with
optimal risk factor control within different countries.
We used complete-case analyses for all primary analyses. The
rate of missing data for the primary analysis was less than 5%, with
systolic BP information missing in 4.1%, smoking information missing
in 2.5% and ASCVD information missing in 2.8% of the population. All
analyses were conducted using SAS 9.4 software (SAS Institute, Cary,
North Carolina). Two-sided P values <0.05 were considered statisti-
cally significant.
3 | RESULTS
3.1 | Study cohort
Among 15 992 patients with T2D beginning second-line therapy from
38 countries enrolled in DISCOVER, 1649 were excluded from Den-
mark, Norway, Sweden and China due to incomplete data at the time
of publication. As such, our analysis included 14 343 participants from
34 countries: 53.8% were male, their mean (SD) age was 57.4 (12.0)
years, mean (SD) body mass index was 29.3 (6.0) kg/m2, and median
(interquartile range) duration of T2D was 4.2 (2.0–8.0) years (Table 1).
The mean duration of diabetes at baseline for our study cohort was
69.1 ± 64.4 months, and 12 121 patients (84.5%) had diabetes for at
least 1 year. Prior to enrolment, 75.9% of patients were on oral mon-
otherapy (8199 metformin, 1047 sulphonylureas, 1164 dipeptidyl
peptidase-4 [DPP-4] inhibitors, 470 others), 20.3% of patients were
on dual therapy (2138 metformin plus a sulphonylurea, 483 metformin
plus a DPP-4 inhibitor, 169 metformin plus other, 114 other combina-
tions) and 3.6% of patients were on triple therapy (215 on metformin
+sulphonylureas+DPP-4 inhibitors, 184 on metformin+sulphonylureas
+thiazolidinedianones, 116 other combinations). Lack of efficacy was
cited as the most common reason for switching to second-line
glucose-lowering treatment, cited in 89% of the study cohort. A total
of 1645 patients (11.8%) had documented ASCVD (coronary artery
disease, cerebrovascular disease, peripheral artery disease), 7568
(52.8%) had history of hypertension, and 559 (4.5%) had history of
albuminuria. Their mean (SD) HbA1c was 67.2 (18.6) mmol/mol and
mean (SD) LDL cholesterol level was 2.82 (1.0) mmol/L. ACE inhibi-
tors/ARBs were prescribed in 38.5% (of overall cohort), beta-blockers
in 14.3%, calcium channel blockers in 15.4% and diuretics were pre-
scribed in 12.7% of the population.
3.2 | Cardiovascular risk factor control
A total of 942 patients (6.6%) were only eligible for two risk factor
metrics, 4350 (30.3%) were eligible for three, 7694 (53.6%) were eligi-
ble for four, and 1357 (9.5%) were eligible for all five metrics. Among
all eligible patients, BP was controlled in 67.5% (9284/13756), statin
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TABLE 1 Baseline characteristics of patients with type 2 diabetes with and without optimal comprehensive cardiovascular risk factor control
in the DISCOVER study
Characteristic
Total
Cardiovascular risk factors with optimal control
P*n = 14 343 Yes n = 3088 No n = 11 255
Demographics
Age, years, mean ± SD 57.4 ± 12.0 54.2 ± 13.5 58.2 ± 11.5 <0.001
Male sex, n (%) 7714 (53.8) 1585 (51.3) 6129 (54.5) 0.002
Self-reported ethnicity, n (%) <0.001
White 3608 (26.4) 582 (19.6) 3026 (28.3)
Black 304 (2.2) 68 (2.3) 236 (2.2)
Mixed 211 (1.5) 43 (1.4) 168 (1.6)
Asian 6310 (46.2) 1548 (52.0) 4762 (44.5)
Hispanic 936 (6.8) 249 (8.4) 687 (6.4)
Arabic 2142 (15.7) 470 (15.8) 1672 (15.6)
Other 160 (1.2) 16 (0.5) 144 (1.3)
Education level, n (%) <0.001
No formal education 397 (3.1) 74 (2.5) 323 (3.2)
Primary (1–6 years) 2028 (15.6) 346 (11.9) 1682 (16.6)
Secondary (7–13 years) 6414 (49.3) 1308 (45.0) 5106 (50.5)
University or higher (≥13 years) 4175 (32.1) 1181 (40.6) 2994 (29.6)
Main working status, n (%) <0.001
Employed 4914 (36.5) 1125 (37.9) 3789 (36.1)
Self-employed 1668 (12.4) 392 (13.2) 1276 (12.1)
Disabled 69 (0.5) 9 (0.3) 60 (0.6)
Not working 3990 (29.6) 913 (30.8) 3077 (29.3)
Retired 2765 (20.5) 515 (17.4) 2250 (21.4)
Health insurance coverage, n (%) <0.001
Private 2029 (15.4) 568 (20.1) 1461 (14.1)
Public/governmental 7647 (57.9) 1480 (52.3) 6167 (59.5)
Mixed 354 (2.7) 66 (2.3) 288 (2.8)
No insurance 3168 (24.0) 717 (25.3) 2451 (23.6)
Tobacco smoking, n (%) <0.001
Non-smoker 9831 (70.3) 2570 (83.2) 7261 (66.6)
Former smoker 2271 (16.2) 518 (16.8) 1753 (16.1)
Current smoker 1889 (13.5) 0 (0.0) 1889 (17.3)
Vitals and laboratory values
Body mass index, kg/m2, mean ± SD 29.3 ± 6.0 28.9 ± 5.8 29.5 ± 6.1 <0.001
Systolic BP, mmHg, mean ± SD 132.4 ± 16.6 123.5 ± 9.5 134.8 ± 17.2 <0.001
Diastolic BP, mmHg, mean ± SD 79.7 ± 10.0 76.2 ± 7.9 80.7 ± 10.2 <0.001
HbA1c, mmol/mol, mean ± SD 67.2 (18.6) 67.2 (17.4) 67.2 (19.0) 0.090
LDL cholesterol, mmol/L, mean ± SD 2.82 (1.0) 2.76 ± 1.02 2.85 ± 0.99 <0.001
Serum creatinine, umol/L, mean ± SD 88.42 ± 88.42 88.42 ± 88.42 88.42 ± 88.42 0.298
Medical history at baseline
Time since T2D diagnosis, months, median (IQR) 50.4 (24.3, 95.9) 49.1 (23.8, 85.6) 51.0 (24.5, 97.5) <0.001
Atherosclerotic cardiovascular disease, n (%) 1645 (11.8) 292 (9.5) 1353 (12.5) <0.001
Heart failure, n (%) 516 (3.6) 57 (1.8) 459 (4.1) <0.001
Chronic kidney disease, n (%) 759 (5.3) 139 (4.5) 620 (5.5) 0.026
Albuminuria, n (%) 559 (4.5) 76 (2.7) 483 (5.0) <0.001
Hypertension, n (%) 7568 (52.8) 1288 (41.7) 6280 (55.8) <0.001
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treatment was prescribed in 43.7% (5775/13208), ACE inhibitor/ARB
treatment was prescribed in 55.6% (5292/9512 of patients with
hypertension or albuminuria), aspirin was prescribed in 53.3%
(876/1645), and 84.4% (12 102/14343) were non-smoking (Table 2).
Overall, 21.5% (3088/14343) of patients had optimal risk factor con-
trol, meaning they had no uncontrolled risk factors. Table 1 shows the
differences in patient and site characteristics between those with and
without optimal combined cardiovascular risk factor control.
Among patients with known history of hypertension, BP was con-
trolled in 57.1% (4185/7332). Among patients who had a lipid panel
checked within a year of baseline, LDL cholesterol 2.59 mmol/L was




Cardiovascular risk factors with optimal control
P*n = 14 343 Yes n = 3088 No n = 11 255
Hyperlipidaemia, n (%) 6852 (47.8) 2129 (69.0) 4723 (42.0) <0.001
Any microvascular complication, n (%) 10 468 (73.0) 2373 (76.9) 8095 (72.0) <0.001
cardiovascular medications
ACE inhibitors/ARBs 5524 (38.5) 1413 (45.8) 4111 (36.5) <0.001
Beta-blockers 2046 (14.3) 330 (10.7) 1716 (15.2) <0.001
Calcium channel blockers 2213 (15.4) 353 (11.4) 1860 (16.5) <0.001
Diuretics 1825 (12.7) 361 (11.7) 1464 (13.0) 0.051
Any lipid-lowering drugs 6824 (47.6) 2658 (86.1) 4166 (37.0) <0.001
High-intensity statins 1662 (13.3) 586 (21.0) 1076 (11.1) <0.001
Low-intensity statins 4706 (32.8) 2066 (66.9) 2640 (23.5) <0.001
Fibrates 623 (4.3) 137 (4.4) 486 (4.3) 0.774
Any anti-platelet drugs 2601 (18.1) 772 (25.0) 1829 (16.3) <0.001
Site characteristics
Type of centre, n (%) <0.001
Primary care centre 4524 (32.5) 1009 (33.4) 3515 (32.2)
General/community hospital 1896 (13.6) 353 (11.7) 1543 (14.2)
University/teaching hospital 2052 (14.7) 400 (13.2) 1652 (15.2)
Specialized diabetes centre 2914 (20.9) 726 (24.0) 2188 (20.1)
Other 2534 (18.2) 531 (17.6) 2003 (18.4)
Location, n (%) <0.001
Urban 11 600 (83.5) 2618 (87.1) 8982 (82.5)
Rural 2295 (16.5) 388 (12.9) 1907 (17.5)
Centre funding, n (%) <0.001
Public/governmental 4049 (29.3) 810 (27.0) 3239 (29.9)
Private 9638 (69.7) 2167 (72.3) 7471 (69.0)
Mixed 133 (1.0) 19 (0.6) 114 (1.1)
Main type of patient referral, n (%) <0.001
Patient self-referral 6400 (46.2) 1279 (42.7) 5121 (47.2)
Primary care referral 7285 (52.6) 1678 (56.0) 5607 (51.7)
Secondary care referral 158 (1.1) 39 (1.3) 119 (1.1)
Estimated number of patients with T2D per month, n (%) <0.001
<10 686 (4.9) 79 (2.6) 607 (5.6)
10–20 584 (4.2) 124 (4.1) 460 (4.2)
21–50 2457 (17.7) 575 (19.0) 1882 (17.3)
>50 10 185 (73.2) 2241 (74.2) 7944 (72.9)
Availability of specialty care at the site, n (%) 5196 (37.3) 920 (30.5) 4276 (39.2) <0.001
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; HbA1c, glycated haemoglobin; IQR, inter-
quartile range; T2D, type 2 diabetes mellitus.
*Comparisons made between two groups using Pearson's chi-squared test or Fisher's exact test for categorical variables or t-test or Wilcoxon rank sum
test for continuous variables.
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among high-risk patients with T2D was low at 21.5% (2048/9510;
Supplement Table 2).
3.3 | Risk factor control by WHO region
Smoking was the most well-controlled risk factor across all WHO
regions, with non-smoking rates varying from 75.6% to 95.1%.
Statin treatment was the least well-controlled risk factor, with more
than half of the eligible study cohort in all WHO regions not being
on a statin; rates of statin use varied from 41.4% to 46.5%. There
was substantial variability in individual and combined cardiovascu-
lar risk factor control across countries and WHO regions (Figure 1
and Tables 2 and 3). Optimal risk factor control ranged across
regions from 19.3% in the Western Pacific to 28.7% in South-
East Asia.
F IGURE 1 Variability among countries in optimal comprehensive cardiovascular risk factor control in patients with type 2 diabetes enrolled in
the DISCOVER study. Median odds ratios (MORs) estimate the median value of the odds ratios from two patients with identical risk factors from
two randomly selected countries. An MOR of 1 indicates no country-level variation in cardiovascular risk factor control, with higher MORs
representing increased variability in risk factor control due to country specific effect, independent of patient and site-level differences
TABLE 3 World Health Organization region-specific rates of cardiovascular risk factor control (%) adjusted for age, sex, atherosclerotic
















Systolic BP < 140 mmHg 70.0 70.3 75.1 57.9 62.9 72.0
Statin treatment 47.9 43.9 48.5 41.9 47.9 43.5
Nonsmoking status 90.0 89.2 96.6 79.6 85.5 78.0
ACE inhibitors/ARBs for
hypertension/albuminuria
53.6 60.8 48.6 60.7 56.1 51.9
Secondary prevention with
aspirin for ASCVD
76.4 45.3 41.3 51.7 65.6 48.7
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BP, blood
pressure.
aValues for all regions are %.
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3.4 | Variability in optimal comprehensive risk
factor control among countries
In the hierarchical model that accounted for patient demographic and
clinical factors, the MOR for optimal risk factor control was 1.42 (95%
confidence interval [CI] 1.23, 1.57), indicating that two hypothetically
identical patients would have 1.42 times different odds in optimal risk
factor control in one country versus another. This variability did not
meaningfully change after adjustment for site characteristics (adjusted
MOR 1.47, 95% CI 1.24, 1.66; Figure 1), suggesting that patient and
site characteristics were not the primary drivers of this observed
variability.
3.5 | Factors associated with optimal
comprehensive risk factor control within countries
In adjusted analyses, the patient factors older age, higher body mass
index, history of hypertension, smoking, and microvascular complica-
tions were associated with decreased odds of optimal risk factor con-
trol, whereas higher education (post-secondary level), history of
hyperlipidaemia and chronic kidney disease were associated with
greater odds of optimal risk factor control (Supplement Table 3).
4 | DISCUSSION
Despite the importance of risk factor management in the prevention
of ASCVD, we found suboptimal rates of cardiovascular risk factor
control in a global study of patients with T2D. Rates of individual risk
factor control ranged from 44% with statin prescription to 84% with
non-smoking status, and only approximately one in five patients had
optimal cardiovascular risk factor control, as defined by no uncon-
trolled risk factors. In addition, there was significant variation among
countries in achievement of optimal comprehensive cardiovascular
risk factor control, which was not explained by differences in patient
and site characteristics. Further investigation is needed to explore the
structural factors across these different healthcare delivery systems
that could be the key drivers of these variations in care.
Prior studies have consistently found that comprehensive cardio-
vascular risk factor control significantly reduces the risk of major car-
diovascular events and death in patients with T2D, both in
primary8,16,17 and secondary7,18 prevention populations. Among
271 174 Swedish patients with T2D, those with multiple cardiovascu-
lar risk factors under control had a similar to no excess risk of major
cardiac events compared with the general population without diabe-
tes.17 The benefits of risk factor control are even more pronounced in
patients with T2D and known ASCVD, at least in absolute terms. In a
post hoc analysis of the Trial Evaluating Cardiovascular Outcomes with
Sitagliptin (TECOS) in patients with diabetes and ASCVD, there was a
stepwise decrease in the risk of the composite of myocardial infarc-
tion, stroke, or cardiovascular death over a median of 3 years of
follow-up with each cardiovascular risk factor controlled.18 As a result,
optimal control of cardiovascular risk factors is strongly supported in
multiple guideline statements for patients with T2D.14,15
Despite this strong evidence base and guideline recommendation,
a large treatment gap is evident in the optimal control of cardiovascu-
lar risk factors in patients with T2D.10,17,19 Among 292 170 patients
with diabetes in a large British outpatient primary care database, only
14.7% had optimal control of glycaemia and all cardiovascular risk fac-
tors including BP, lipids, statins and smoking a year after their initial
diagnosis,19 despite higher rates of prescription of ACE inhibitors/
ARBs, statin and anti-hypertensive medications ranging from 47% to
71% compared to our study cohort. Among all adults with T2D
enrolled in a nationally representative survey in the United States,
only 16% had optimal control of glycaemia and all cardiovascular risk
factors. Only 30% of patients in TECOS had optimal cardiovascular
risk factor control, even in a secondary prevention population in a
clinical trial setting where rates of aspirin, statin and ACE inhibitor/
ARB prescription were 80% and higher.18 This treatment gap may be
even more pronounced in low-/middle-income countries, with the
International Diabetes Management Practice Study showing that only
3.6% of patients had optimal control of the combination of glucose
level, BP and lipids.20 Our study extends the results of the previous
studies by providing important insights into contemporary patterns of
cardiovascular risk factor control in a real-world setting globally
(including in several countries and regions that have little or no previ-
ously collected data), finding that these treatment gaps continue to
persist with only one in five patients having optimal comprehensive
cardiovascular risk factor control. Overall rates of prescription of anti-
hypertensive medications and ACE inhibitors/ARBs in our study
cohort was also lower than some of the studies above, being 50% and
39%, respectively. Our study further shows the high variability in care
across different regions around the world, even after accounting for
differences in patient and site characteristics. As such, it is possible
that there are other unmeasured socio-economic or structural factors
in processes of care for these patients that may be contributing to this
high variability in care that was not captured by the variables collected
in the study.
Our study highlights a critical opportunity to improve care and
outcomes in patients with T2D globally. Most patients with T2D have
one or more cardiovascular risk factors, and consistently prioritizing
control of factors such as hypertension, smoking, proteinuria, and
dyslipidaemia could have a substantial global impact on the cardiovas-
cular morbidity and mortality associated with T2D. Certain patient
factors such as older age, obesity, known history of hypertension and
history of microvascular complications of diabetes were associated
with poor optimal cardiovascular risk factor control in our study
cohort. Education and increased awareness of these higher-risk
patient factors among physicians and care providers can help improve
cardiovascular risk factor control among these patients. Never has the
imperative to focus and increase the efforts on risk factor control
been more important than now, with recent US data suggesting
increases in cardiac events among young and middle-aged patients
with T2D along with a plateau in improvements in older patients.12
While identifying new drugs and therapies that decrease
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cardiovascular risk is important, the results of the present study sug-
gest that we also need to focus on optimizing well-established inter-
ventions for reducing cardiovascular risk – interventions with an
extensive evidence base that are relatively affordable. Gaps in provi-
sion of care (due to poor identification or lack of resources) and
patient adherence to and engagement with treatment may be respon-
sible for poor risk factor control. These gaps may also differ among
countries. Nearly 80% of people with diabetes live in low-/middle-
income countries,21 and many do not have access to basic healthcare
and medications.22,23 Due to the low cost of interventions targeting
cardiovascular risk factor control, they are likely to not only be cost-
effective, but cost-saving, especially in higher-risk diabetes patients,
emphasizing the importance of implementing these even in relatively
resource-poor healthcare environments. Future research should focus
on identifying effective strategies to increase cardiovascular risk fac-
tor control in patients with T2D across countries with different econ-
omies, societal structures, and healthcare systems.
Our findings should be interpreted in the context of the follow-
ing potential limitations. First, DISCOVER includes a wide range of
countries across six continents and attempted to enrol a representa-
tive population within each included country; however, it is unclear
if our findings truly reflect care within each country or all generaliz-
able outside of the included countries. Given their participation in
DISCOVER, it is possible that participating sites may be more
focused on quality care, which would indicate that our estimates are
best-case scenarios. Second, given the relatively low prevalence of
ASCVD in our cohort, the results may not be reflective of rates of
cardiovascular risk factor control for secondary prevention. Our
study reflects control of risk factors among patients who are at a rel-
atively early stage of diabetes, with the mean duration of diabetes
being ~4 years, even though >80% of the study population had dia-
betes for at least 1 year or longer. All patients in the study, by virtue
of the inclusion criteria, required escalation of diabetes therapy. Our
study cohort also had lower rates of comorbidities such as chronic
kidney disease and albuminuria, making the cohort lower-risk, poten-
tially affecting the generalizability of the findings. Third, lifestyle
counselling on physical activity and diet is also an important aspect
of cardiovascular risk factor control, along with adherence to medi-
cations, but these measures could not be accounted for in the pre-
sent study owing to high rates of missing data. Fourth, we applied
the same definition of risk factor control across all countries, realiz-
ing that there may be some country-specific differences in guidelines
for quality care.
In conclusion, in a global study of 14 343 patients with relatively
early-stage T2D across 34 countries, the majority did not have optimal
control of cardiovascular risk factors, with a large variation in risk fac-
tor control among countries. This variability was not explained by dif-
ferences in patient, provider, or site characteristics, suggesting that it
might be related to structural differences in healthcare systems. To
improve long-term cardiovascular outcomes in patients with T2D, bet-
ter strategies are needed to implement current guidelines to provide
comprehensive cardiovascular risk factor control in all patients
with T2D.
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